Metabolic biomarkers study in newly diagnosed ovarian cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study looks at certain substances in the body (called metabolic biomarkers) and how they relate to how well patients do after treatment. It is for women who have just been diagnosed with high-grade serous ovarian cancer and have not yet had any treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have been diagnosed with high-grade serous ovarian cancer (a common type)
- This is your first diagnosis of ovarian cancer and you have not received any chemotherapy or other cancer treatment before surgery
- You have not had any other cancer in the past
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at tumor tissue from ovarian cancer patients to find “biomarkers,” or lab signals, that may predict how the disease behaves or how it might respond to treatment. You may be asked for a biopsy of the relapsed (coming back) tumor or to use an existing archived tumor sample.
This study is testing new blood tests that might help detect ovarian cancer earlier by looking for specific markers. It involves people with suspected ovarian cancer and healthy volunteers, and aims to improve how we diagnose the disease.
This study looks at metastatic ovarian cancer by analyzing many types of patient data (from “multi-omics,” which means different kinds of lab and biological information). It may help doctors better understand the disease and improve future care.
This study aims to use your tumor and blood samples to find the best treatment for your ovarian cancer. It may help tailor your care based on your unique cancer biology.
This study is testing a new blood test to help find ovarian cancer early in women who are at average risk. By joining, you may help improve early detection, which could lead to better outcomes.
This trial tests a new blood test (OCS) that may help detect if ovarian cancer comes back after initial treatment. It is for people whose CA125 levels were normal at diagnosis.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.